These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36961847)

  • 1. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
    Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
    PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy.
    Grasselli G; Zanella A; Carlesso E; Florio G; Canakoglu A; Bellani G; Bottino N; Cabrini L; Castelli GP; Catena E; Cecconi M; Cereda D; Chiumello D; Forastieri A; Foti G; Gemma M; Giudici R; Grazioli L; Lombardo A; Lorini FL; Madotto F; Mantovani A; Mistraletti G; Mojoli F; Mongodi S; Monti G; Muttini S; Piva S; Protti A; Rasulo F; Scandroglio AM; Severgnini P; Storti E; Fumagalli R; Pesenti A;
    JAMA Netw Open; 2022 Oct; 5(10):e2238871. PubMed ID: 36301541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
    CORIMUNO-19 Collaborative group
    Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
    Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
    Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.
    Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
    Int J Infect Dis; 2023 Jan; 126():87-93. PubMed ID: 36403818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
    Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
    JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
    Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
    PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
    Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P;
    Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA.
    Rich C; Eriksson D; Dolfi F; Jablonska K; Dabbous F; Nazir J
    Clin Exp Immunol; 2022 Apr; 207(2):218-226. PubMed ID: 35020840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.
    Aomar-Millán IF; Salvatierra J; Hernández-Quero J
    Intern Emerg Med; 2021 Jun; 16(4):1105-1106. PubMed ID: 33694056
    [No Abstract]   [Full Text] [Related]  

  • 16. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.
    Yurttutan S; Gullu UU; Ipek S
    Intern Emerg Med; 2021 Jun; 16(4):1101-1103. PubMed ID: 33598871
    [No Abstract]   [Full Text] [Related]  

  • 17. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
    Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
    Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
    Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
    Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
    J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.